Table 2 Peri-Procedural Characteristics and Outcomes of the Study Population
| Â | Total (n = 60) | NTA (n = 25) | TA (n = 35) | p Value |
|---|---|---|---|---|
Infarct artery (%) | Â | Â | Â | Â |
   LAD | 26 (43.3) | 12 (48.0) | 14 (40.0) | 0.344 |
   LCx | 12 (20.0) | 6 (24.0) | 6 (17.1) | 0.210 |
   RCA | 22 (36.7) | 9 (36.0) | 13 (37.1) | 0.416 |
Multivessel disease (%) | 26 (43.3) | 9 (36.0) | 17 (48.6) | 0.128 |
Thrombus score | Â | Â | Â | Â |
   2 | 22 (36.7) | 8 (32.0) | 14 (40.0) | 0.224 |
   3 | 23 (38.3) | 11 (44.0) | 12 (34.3) | 0.419 |
   4 | 4 (6.7) | 2 (8.0) | 2 (5.7) | 0.426 |
Adjunctive Pharmacologic Therapy | Â | Â | Â | Â |
   Glycoprotein IIb/IIIa inhibitor (%) | 35 (58.3) | 13 (52.0) | 22 (62.9) | 0.514 |
   Bivalirudin (%) | 25 (41.7) | 11 (44.0) | 14 (40.0) | 0.664 |
Stent type | Â | Â | Â | Â |
   Bare-metal | 41 (68.3) | 16 (64.0) | 25 (71.4) | 0.517 |
   Drug-eluting | 19 (31.7) | 8 (32.0) | 11 (31.4) | 0.736 |
Mean peak creatine kinase peak (IU/L) | 2177 ± 1579 | 2321 ± 1271 | 2142 ± 1643 | 0.513 |
ST-segment resolution (%) | 34 (56.7) | 10 (40.0) | 24 (68.6) | 0.036 |
Post PCI TIMI flow grade (%) | Â | Â | Â | Â |
   > 2 | 58 (96.7) | 24 (96.0) | 34 (97.1) | 0.987 |
Post PCI MBG (%) | Â | Â | Â | Â |
   > 2 | 42 (70.0) | 11 (44.0) | 31 88.6) | 0.001 |
Mean PCI to CMR time | Â | Â | Â | Â |
   Scan 1, hours | 34.4 ± 17.3 | 36.6 ± 16.2 | 34.0 ± 17.6 | 0.435 |
   Scan 2, days | 243 ± 62 | 222 ± 52 | 247 ± 69 | 0.212 |